Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Portable Sensor Detects Gluten In Foods For Those With Celiac Disease

XTALKS VITALS NEWS

Nima

Nima is a small but highly-sensitive device capable of detecting trace amounts of gluten in food. Image courtesy of Nima.

Tweetables from this article:

Tweet: 3 million people affected by #celiac disease in the US http://ctt.ec/43IMN+3 million people affected by celiac disease in the US.

Tweet: FDA: Maximum concentration of gluten for “gluten-free” foods is 20 ppm http://ctt.ec/4rdbB+85,000 to 110,000 US patients experience recurring Clostridium difficile infections.

Share this!

July 8, 2016 | by Sarah Massey, M.Sc.

Gluten intolerance and celiac disease can be difficult to manage, especially when consuming food prepared outside the home. Since even small amounts of the protein can trigger serious reactions, how can someone be sure a menu item really is “gluten-free”?

Enter the Nima – a small but highly-sensitive device capable of detecting trace amounts of gluten in food. Nima was developed by MIT graduates Shireen Yates and Scott Sundvor, who are the CEO and Chief Product Officer for the company, respectively.

Celiac disease is an autoimmune disorder in which a patient suffers intestinal damage when gluten protein is eaten. The disease affects about 3 million people in the US, according to the National Institutes of Health (NIH). Millions more are thought to suffer from other types of gluten intolerance, according to the National Foundation for Celiac Awareness.

The three-inch-tall Nima device utilizes disposable capsules, into which individuals can insert a small amount of food or liquid. Once inserted into the Nima, the food-filled capsule comes in contact with a proprietary solution containing gluten-detecting antibodies.

In just over two minutes, the digital display indicates whether the food tested does or does not contain gluten. The results are automatically sent to a Nima app which allows users to enter additional information – such as where they ate, what dish was tested and whether it contained gluten – that is publicly available to all Nima users.



“Right now, we don’t know what’s in our food, whether it is allergens, pesticides, or other harmful chemicals,” Sundvor told MIT News. “There’s not a good way to get that data. We want to give people the ability to understand their food better and how it affects their health.”

As the maximum concentration of gluten allowable by the US Food and Drug Administration (FDA) for “gluten-free” foods is 20 parts per million (ppm), Nima can detect the protein at this concentration. Nima owes its high level of sensitivity to the immunoassay developed primarily by the company’s lead scientist and MIT alumnus, Dr. Jingqing Zhang.

At the core of Nima’s immunoassay technology are custom antibodies capable of detecting miniscule amounts of gluten in a sample. Once the antibodies bind to a gluten molecule, it triggers a colorimetric reaction which can then be detected by an optical reader.

Nima’s simplified display allows diners to make quick choices about whether or not a dish is safe to eat. A “gluten found” message is displayed if any gluten is detected by the device, otherwise the sensor will display a smiley face indicating that the food contains less than 20 ppm of the protein.

Even foods designed to be gluten-free can contain trace amounts of gluten, particularly if they come in contact with surfaces contaminated with the allergen. “It’s the equivalent to finding a breadcrumb in an entire plate of food,” said Sundvor.


Keywords: Food, Autoimmune Disorder, Intolerance


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


FDA Approves Puma Biotechnology’s Extended Adjuvant Therapy for Breast

July 19, 2017 - Puma Biotechnology’s breast cancer drug Nerlynx (neratinib) has been approved by the US Food and Drug Administration (FDA).

Featured In: Biotech News


CAR-T Cell Therapy Shows Promise as Leukemia Treatment in Early Stage Clinical Trial

July 19, 2017 - About 70 percent of clinical trial participants with chronic lymphocytic leukemia experienced tumor shrinkage after being treated with CAR-T immunotherapy, according to researchers at Fred Hutchinson Cancer Research Center.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.